Early-stage multiple sclerosis: What are the treatment options?SORENSEN, Per Soelberg.Drugs (Basel). 2004, Vol 64, Num 18, pp 2021-2029, issn 0012-6667, 9 p.Article

Antibodies to IFN-beta: The danish national IFN-beta projectSORENSEN, Per Soelberg.Neurology. 2003, Vol 61, Num 9, pp S27-S28, issn 0028-3878, SUP5Conference Paper

Disease evolution, clinical studies, and long term clinical outcomes in multiple sclerosisFERNANDEZ Y FERNANDEZ, Oscar; FORD, Corey C; SØRENSEN, Per Soelberg et al.Journal of neurology. Supplement. 2006, Vol 253, Num 6, issn 0939-1517, 53 p.Conference Proceedings

The gap between effect of drugs and effectiveness of treatmentsSORENSEN, Per Soelberg.Journal of the neurological sciences. 2007, Vol 259, Num 1-2, pp 128-132, issn 0022-510X, 5 p.Conference Paper

Differential microRNA expression in blood in multiple sclerosisSØNDERGAARD, Helle Bach; HESSE, Dan; KRAKAUER, Martin et al.Multiple sclerosis. 2013, Vol 19, Num 14, pp 1849-1857, issn 1352-4585, 9 p.Article

Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosisBÖRNSEN, Lars; KHADEMI, Mohsen; OLSSON, Tomas et al.Multiple sclerosis. 2011, Vol 17, Num 1, pp 32-42, issn 1352-4585, 11 p.Article

Gender and autoimmune comorbidity in multiple sclerosisMAGYARI, Melinda; KOCH-HENRIKSEN, Nils; PFLEGER, Claudia C et al.Multiple sclerosis. 2014, Vol 20, Num 9, pp 1244-1251, issn 1352-4585, 8 p.Article

Reproduction and the risk of multiple sclerosisMAGYARI, Melinda; KOCH-HENRIKSEN, Nils; PFLEGER, Claudia C et al.Multiple sclerosis. 2013, Vol 19, Num 12, pp 1604-1609, issn 1352-4585, 6 p.Article

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosisVARTANIAN, Timothy K; ZAMVIL, Scott S; FOX, Edward et al.Neurology. 2004, Vol 63, Num 11, pp S42-S49, issn 0028-3878, SUP5Article

Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitisJORGENSEN, Signe Humle; SORENSEN, Per Soelberg.Journal of the neurological sciences. 2005, Vol 233, Num 1-2, pp 61-65, issn 0022-510X, 5 p.Conference Paper

IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesionsJORGENSEN, Signe Humle; STORM, Nicolas; JENSEN, Poul Erik Hyldgaard et al.Experimental brain research. 2007, Vol 178, Num 4, pp 462-469, issn 0014-4819, 8 p.Article

The role of intravenous immunoglobulin in the treatment of multiple sclerosisSORENSEN, Per Soelberg.Journal of the neurological sciences. 2003, Vol 206, Num 2, pp 123-130, issn 0022-510X, 8 p.Conference Paper

The effect of β-interferon therapy on myelin basic protein-elicited CD4+ Tcell proliferation and cytokine production in multiple sclerosisHEDEGAARD, Chris J; KRAKAUER, Martin; BENDTZEN, Klaus et al.Clinical immunology (Orlando, Fla. Print). 2008, Vol 129, Num 1, pp 80-89, issn 1521-6616, 10 p.Article

Multiple sclerosis after infectious mononucleosisNIELSEN, Trine Rasmussen; ROSTGAARD, Klaus; NIELSEN, Nete Munk et al.Archives of neurology (Chicago). 2007, Vol 64, Num 1, pp 72-75, issn 0003-9942, 4 p.Article

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosisCHRISTENSEN, Jeppe Romme; BÖRNSEN, Lars; KHADEMI, Mohsen et al.Multiple sclerosis. 2013, Vol 19, Num 7, pp 877-884, issn 1352-4585, 8 p.Article

Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administrationROSS, Christian; CLEMMESEN, Katja Maria; SVENSON, Morten et al.Annals of neurology. 2000, Vol 48, Num 5, pp 706-712, issn 0364-5134Article

Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosisPETERSEN, Bodil; BENDTZEN, Klaus; KOCH-HENRIKSEN, Nils et al.Multiple sclerosis. 2006, Vol 12, Num 3, pp 247-252, issn 1352-4585, 6 p.Article

Cognitive impairment in newly diagnosed multiple sclerosis patients : A 4-year follow-up studyJØNSSON, Agnete; ANDRESEN, Jente; STORR, Lars et al.Journal of the neurological sciences. 2006, Vol 245, Num 1-2, pp 77-85, issn 0022-510X, 9 p.Conference Paper

Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosisDOGONOWSKI, Anne-Marie; SIEBNER, Hartwig R; SØRENSEN, Per Soelberg et al.Multiple sclerosis. 2013, Vol 19, Num 5, pp 559-566, issn 1352-4585, 8 p.Article

Effect of early interferon treatment on conversion to definite multiple sclerosis : a randomised studyCOMI, Giancarlo; FILIPPI, Massimo; MARTINELLI, Vittorio et al.Lancet (British edition). 2001, Vol 357, Num 9268, pp 1576-1582, issn 0140-6736Article

Defining the clinical course of multiple sclerosis: The 2013 revisionsLUBLIN, Fred D; REINGOLD, Stephen C; BEBO, Bruce et al.Neurology. 2014, Vol 83, Num 3, pp 278-286, issn 0028-3878, 9 p.Article

The relationship between MRI and PET changes and cognitive disturbances in MSSØRENSEN, Per Soelberg; JØNSSON, Agnete; MATHIESEN, Henrik Kahr et al.Journal of the neurological sciences. 2006, Vol 245, Num 1-2, pp 99-102, issn 0022-510X, 4 p.Conference Paper

Remyelination is extensive in a subset of multiple sclerosis patients. CommentarySMITH, Kenneth J; PATRIKIOS, Peter; LASSMANN, Hans et al.Brain. 2006, Vol 129, issn 0006-8950, 3147-3149,3165-3172 [11 p.], 12Article

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisSORENSEN, Per Soelberg; ROSS, Christian; STENAGER, Egon et al.Lancet (British edition). 2003, Vol 362, Num 9391, pp 1184-1191, issn 0140-6736, 8 p.Article

Immunogenicity and tolerability of an investigational formulation of interferon-β1a : 24-and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase iiib study in adults with multiple sclerosisGIOVANNONI, Gavin; BARBARASH, Olga; CASSET-SEMANAZ, Florence et al.Clinical therapeutics. 2007, Vol 29, Num 6, pp 1128-1145, issn 0149-2918, 18 p.Article